<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03427827</url>
  </required_header>
  <id_info>
    <org_study_id>B2017-097-01</org_study_id>
    <nct_id>NCT03427827</nct_id>
  </id_info>
  <brief_title>Camrelizumab (PD-1 Antibody) After Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (PACIFIC-NPC)</brief_title>
  <official_title>Camrelizumab (PD-1 Antibody) After Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Randomised Controlled, Phase 3 Trial (PACIFIC-NPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is aimed to investigate whether adjuvant PD-1 antibody treatment could improve
      survival in locoregionally advanced nasopharyngeal carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this multicenter, randomised controlled, phase 3 trial, patients with stage III-IVA
      (AJCC/UICC 8th system, except T3-4N0 and T3N1) non-metastatic nasopharyngeal carcinoma will
      be randomized in a 1:1 ratio to recieve PD-1 antibody for 12 doses every 3 weeks or
      observation after curative chemoradiation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>calculated from the date of randomisation to the date of locoregional failure, distant failure, or death from any cause, whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>calculated from date of randomisation to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant metastasis-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>calculated from date of randomisation to the first distant failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>locoregional recurrence-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>calculated from date of randomisation to the first locoregional failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events (AEs) and severe adverse events (SAE)</measure>
    <time_frame>3 years</time_frame>
    <description>graded according to NCI CTCAE 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (QoL)</measure>
    <time_frame>1 year</time_frame>
    <description>the change of QoL from randomization to 12 months after chemoradiation, graded according to EORTC QLQ-C30 V3.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Nasopharyngeal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Adjuvant PD-1 antibody arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm will receive PD-1 antibody (SHR-1210), 200mg, ivdrip (&gt;30 minutes), d1, q3w × 12 cycles, begining at 4-6 weeks after chemoradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to this arm will receive no aditional treatment after chemoradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab is an antibody targeting PD-1 developed by Jiangsu Hengrui Medicine, China.</description>
    <arm_group_label>Adjuvant PD-1 antibody arm</arm_group_label>
    <other_name>SHR-1210</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed nasopharyngeal carcinoma.

          -  Tumor staged as III-IVA (AJCC 8th, except T3N0-1 or T4N0).

          -  Completed protocol-specified curative chemoradiotherapy, including gemcitabine and
             cisplatin induction chemotherapy, intensity-modulated radiotherapy, and concurrent
             cisplatin chemotherapy.

          -  Eastern Cooperative Oncology Group performance status ≤1.

          -  Adequate marrow function: neutrocyte count≥1.5×10e9/L, hemoglobin ≥90g/L and platelet
             count ≥100×10e9/L.

          -  Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) ≤2.5×upper limit of
             normal (ULN), and bilirubin ≤ 1.5×ULN.

          -  Adequate renal function: creatinine clearance rate ≥ 60 ml/min (Cockcroft-Gault
             formula).

          -  Patients must be informed of the investigational nature of this study and give written
             informed consent.

          -  Women of childbearing potential (WOCBP) who are sexually active must be willing to
             adhere to effective contraception during treatment and for 1 year after the last dose
             of study drug. Men who are sexually active with WOCBP must be willing to adhere to
             effective contraception during treatment and for 1 year after the last dose of the
             study drug.

        Exclusion Criteria:

          -  Age &gt; 65 or &lt; 18.

          -  Hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA &gt;1×10e3
             copies/ml or 200IU/ml

          -  Hepatitis C virus (HCV) antibody positive

          -  Has active autoimmune disease, except type I diabetes, hypothyroidism treated with
             replacement therapy, and skin disease that doesn't require systemic treatment (e.g.,
             vitiligo, psoriasis, or alopecia).

          -  Has any condition that required systemic corticosteroid (equivalent to prednisone
             &gt;10mg/d) or other immunosuppressive therapy within 28 days before informed consent.
             Patients received systemic corticosteroid equivalent to prednisone ≤10mg/d, inhale or
             topical corticosteroid will be allowed.

          -  Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with
             adequately treated active TB over 1 year ago will be allowed.

          -  Has a known history of interstitial lung disease.

          -  Has received a live vaccine within 30 days before informed consent or will receive a
             live vaccine in the near future.

          -  Is pregnant or breastfeeding.

          -  Prior malignancy within 5 years, except in situ cancer, adequately treated
             non-melanoma skin cancer, and papillary thyroid carcinoma.

          -  Has known allergy to large molecule protein products or any compound of camrelizumab.

          -  Has a known history of human immunodeficiency virus (HIV) infection.

          -  Any other condition, including symptomatic heart failure, unstable angina, myocardial
             infarction, active infection requiring systemic therapy, mental illness or
             domestic/social factors, deemed by the investigator to be likely to interfere with a
             patient's ability to sign informed consent, cooperate and participate in the study, or
             interferes with the interpretation of the results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Ma, MD</last_name>
    <phone>+862087343469</phone>
    <email>majun@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>First People's Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ning Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou Medical University Cancer Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ya-Wei Yuan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Panyu central hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guo-Rong Zhou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Ma, M.D.</last_name>
      <phone>+86-20-87343469</phone>
      <email>majun2@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jun Ma, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiao-Dong Zhu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Feng Jin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guo-Qing Hu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guo-Qing Hu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guang-Yuan Hu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kun-Yu Yang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liang-Fang Shen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mei SHI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 3, 2018</study_first_submitted>
  <study_first_submitted_qc>February 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>October 6, 2019</last_update_submitted>
  <last_update_submitted_qc>October 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jun Ma, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>PD-1 antibody</keyword>
  <keyword>Adjuvant treatment</keyword>
  <keyword>Immune checkpoint inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Complete de‐identified patient data set</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>For 2 years started from 12 months after publication of the primary trial report.</ipd_time_frame>
    <ipd_access_criteria>Authoritative researchers who provide a methodologically sound proposal for individual participant data meta‐analysis.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

